Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis

Overview of attention for article published in Frontiers in endocrinology, June 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 17 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 4,848 followers.

New Research: Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis: Empagliflozin (EMPA) is a novel sodium-glucose cotransporter 2 inhibitor (SGLT2i) that… https://t.co/CRhopaCevB #En

17 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.